BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35316453)

  • 1. The role of lncRNA OIP5-AS1 in cancer development and progression.
    Zheng C; Chu M; Chen Q; Chen C; Wang ZW; Chen X
    Apoptosis; 2022 Jun; 27(5-6):311-321. PubMed ID: 35316453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA Opa interacting protein 5-antisense RNA 1 (OIP5-AS1) promotes the migration, invasion and epithelial-mesenchymal transition (EMT) through targeting miR-147a/insulin-like growth factor 1 receptor (IGF1R) pathway in cervical cancer tissues and cell model.
    Zhang L; Cai Y; Tian C; Li Y; Ma K; Gao X; Liu L; Jiang Y; Wen W; Ma Z
    J Obstet Gynaecol Res; 2022 May; 48(5):1222-1232. PubMed ID: 35233882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6.
    Wang Y; Li L; Zhang X; Zhao X
    J Ovarian Res; 2022 Feb; 15(1):25. PubMed ID: 35168644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA OIP5-AS1 serves as an oncogene in laryngeal squamous cell carcinoma by regulating miR-204-5p/ZEB1 axis.
    Wang H; Qian J; Xia X; Ye B
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2177-2184. PubMed ID: 32009213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA OIP5-AS1 targets ROCK1 to promote cell proliferation and inhibit cell apoptosis through a mechanism involving miR-143-3p in cervical cancer.
    Song L; Wang L; Pan X; Yang C
    Braz J Med Biol Res; 2020; 53(1):e8883. PubMed ID: 31939597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNA OIP5-AS1 Suppresses Cell Proliferation and Invasion of Endometrial Cancer by Regulating PTEN/AKT via Sponging miR-200c-3p.
    Liu Y; Cai X; Cai Y; Chang Y
    J Immunol Res; 2021; 2021():4861749. PubMed ID: 34368370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma.
    Zhong J; Chen J; Wang B; Zhou Z; Shen Y; Gong Y; Tan F; Yuan C
    Curr Pharm Des; 2021; 27(46):4699-4706. PubMed ID: 34579624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA OIP5-AS1 targets Wnt-7b to affect glioma progression via modulation of miR-410.
    Sun WL; Kang T; Wang YY; Sun JP; Li C; Liu HJ; Yang Y; Jiao BH
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30498093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA OIP5-AS1 promotes the progression of oral squamous cell carcinoma via regulating miR-338-3p/NRP1 axis.
    Li M; Ning J; Li Z; Fei Q; Zhao C; Ge Y; Wang L
    Biomed Pharmacother; 2019 Oct; 118():109259. PubMed ID: 31369989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA OIP5-AS1 functions as an oncogene in lung adenocarcinoma through targeting miR-448/Bcl-2.
    Deng J; Deng H; Liu C; Liang Y; Wang S
    Biomed Pharmacother; 2018 Feb; 98():102-110. PubMed ID: 29247949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA OIP5-AS1 promotes the growth of gastric cancer through the miR-367-3p/HMGA2 axis.
    Tao Y; Wan X; Fan Q; Wang Y; Sun H; Ma L; Sun C; Wu Y
    Dig Liver Dis; 2020 Jul; 52(7):773-779. PubMed ID: 31959478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA OPA-interacting protein 5 antisense transcript 1 upregulated SMAD3 expression to contribute to metastasis of cervical cancer by sponging miR-143-3p.
    Chen X; Xiong D; Yang H; Ye L; Mei S; Wu J; Chen S; Shang X; Wang K; Huang L
    J Cell Physiol; 2019 Apr; 234(4):5264-5275. PubMed ID: 30341904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies.
    Ghafouri-Fard S; Dashti S; Farsi M; Hussen BM; Taheri M
    Biomed Pharmacother; 2021 May; 137():111366. PubMed ID: 33601149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
    Zhang X; Li D; Jia C; Cai H; Lv Z; Wu B
    Cell Death Dis; 2021 Jun; 12(6):617. PubMed ID: 34131102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA OIP5-AS1 promotes cell proliferation and migration and induces angiogenesis via regulating miR-3163/VEGFA in hepatocellular carcinoma.
    Shi C; Yang Q; Pan S; Lin X; Xu G; Luo Y; Zheng B; Xie X; Yu M
    Cancer Biol Ther; 2020 Jul; 21(7):604-614. PubMed ID: 32329664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling.
    Zhang Y; Guo S; Wang S; Li X; Hou D; Li H; Wang L; Xu Y; Ma B; Wang H; Jiang X
    Ecotoxicol Environ Saf; 2021 Sep; 220():112376. PubMed ID: 34051661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA opa-interacting protein 5 antisense transcript 1 promotes proliferation and invasion through elevating integrin α6 expression by sponging miR-143-3p in cervical cancer.
    Yang J; Jiang B; Hai J; Duan S; Dong X; Chen C
    J Cell Biochem; 2019 Jan; 120(1):907-916. PubMed ID: 30188591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA OIP5-AS1 promotes the stemness of lung cancer cells through enhancing Oct4 mRNA stability.
    Mao C; Li X
    Environ Toxicol; 2022 May; 37(5):1104-1112. PubMed ID: 35044041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA OIP5-AS1 promotes pancreatic cancer cell growth through sponging miR-342-3p via AKT/ERK signaling pathway.
    Meng X; Ma J; Wang B; Wu X; Liu Z
    J Physiol Biochem; 2020 May; 76(2):301-315. PubMed ID: 32157498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.